A Better Newspaper

US Strikes on Iran Enter Seventh Night as Both Sides Test Escalation Limits

The US military said it is degrading Iran's military capabilities in a seventh consecutive night of strikes, while Tehran accused Washington of targeting civilian infrastructure. Analysis suggests Iran's leadership believes further escalation will pressure the US into offering the security guarantees and economic relief it seeks, framing the return to conflict as a calculated bid rather than an uncontrolled slide toward all-out war.

Context: For a US investor the key transmission channel is energy: Iran's proximity to the Strait of Hormuz means the tail risk is a disruption of roughly a fifth of global seaborne oil. Prediction markets are pricing both an actual US ground invasion and the loss of Iranian control over the Kharg Island oil terminal as unlikely, suggesting the crowd sees this as a bounded air campaign rather than a regime-ending war — a useful check against the more alarmist framing.

Polymarket: US invades Iran before 2027 23% ▼1 pts since yesterday

China's Moonshot Triggers a Second 'DeepSeek Moment' — and the Cracks Show in Oracle's Credit

A surprise model release from Chinese startup Moonshot sent AI and semiconductor stocks sharply lower Friday, ending the week down and reviving memories of last year's DeepSeek selloff. Retail traders crowded into leveraged single-stock and index funds were hit hardest as the move reversed AI-winner assumptions overnight. Separately, a gauge of Oracle's credit risk hit a fresh all-time high as concerns grew over the company's aggressive cash burn and the future profitability of its AI investments amid the new low-cost Chinese competitor.

Context: The tell here isn't the equity dip — it's Oracle's credit. When a cheaper model appears, the market's first instinct is to question the ROI on hyperscaler capex, and CDS spreads on the most levered AI-infrastructure balance sheets are the cleanest read on that doubt. Watch the spread between private AI-infra valuations (still climbing) and public credit stress (now widening) — that divergence is the trade.

Databricks Marks Itself Up to $118B With Coatue-Led Round — Private AI Valuations Ignore the Public Selloff

Databricks is finalizing a funding round announced Thursday; the Wall Street Journal reports it will add $3 billion to the balance sheet, with Coatue leading. The company disclosed the deal without stating the raise amount. (Note: the source's headline cites a $188B valuation while its body text states $118B — the figure is inconsistent in the reporting.)

Context: The timing is the story: a top-tier private AI name is raising at a fresh markup the same week a Chinese model gutted public AI multiples and pushed Oracle's credit risk to a record. Late-stage private capital is still underwriting AI-native platforms as durable winners even as public markets reprice the capex-heavy incumbents. If you're a funder, the arbitrage isn't in either market — it's in the widening gap between them.

AI Infrastructure Turns to Debt: General Compute Lands $400M as Equity Gets Pickier

AI inference cloud operator General Compute secured $400 million in debt financing underwritten by Upper90, with an initial $100 million drawdown and additional funds available as customer demand grows. Unlike most AI infrastructure providers, General Compute is structuring the financing to draw capital in step with demand rather than raising it all upfront.

Context: Watch the shift from equity to demand-linked debt in AI infrastructure. Structuring drawdowns against contracted customer demand is how you finance capex-heavy buildouts without betting the whole balance sheet on a model landscape that just proved it can shift overnight (see the Moonshot selloff). For private-credit players, contracted-demand-backed AI-infra paper is an emerging asset class — and Upper90 is early.

The Biotech IPO Window Is Cracking Open — Blue Owl-Backed Latigo Files

Latigo Biotherapeutics filed for an IPO, joining a growing list of biotech firms considering going public as soon as this quarter. The company is backed by Blue Owl.

Context: After a multi-year drought, a clustering of biotech S-1s signals the IPO window is reopening for the sector — capital is rotating out of the crowded AI trade toward names with defined catalysts. If public appetite holds, expect a wave of crossover and late-stage privates to accelerate their timelines; the early-quarter filers set the pricing benchmark everyone else follows.

Netflix Projects Weakest Revenue Growth in Three Years

Netflix shares slid after the streaming giant projected its weakest revenue increase in three years, disappointing growth forecasts.

Context: The streaming maturity story is now hard data: even the category winner is guiding to its slowest growth since 2023, confirming saturation in subscriber-led models. The remaining growth levers — ad tiers, live events, gaming, password-sharing crackdowns — are increasingly tapped, which reframes Netflix as a cash-flow story rather than a growth story and reprices the whole streaming cohort accordingly.

New DraftKings Class Action Targets Website Tracking via Data-Broker Software

A new class action alleges DraftKings used data broker software on its website to secretly collect data about visitors.

Context: This fits the ongoing wave of wiretapping/pixel-tracking privacy suits (CIPA, VPPA, and analogous state statutes) that have become a high-volume, low-individual-value docket attractive to funders on aggregate. Gambling operators are a natural next target given the sensitivity of the data and deep-pocketed defendants.

Federal Circuit Affirms PTAB Obviousness Findings Against Slingshot Printhead Patents

The Federal Circuit issued two decisions affirming PTAB final written decisions that found claims of three Slingshot Printing LLC patents unpatentable as obvious, in Slingshot Printing LLC v. Canon U.S.A., Inc. The rulings followed inter partes review proceedings Canon brought against the printhead patents.

Jacksonville Area Legal Aid Collects $37K Cy Pres Award in Landlord-Tenant Class Action

Jacksonville Area Legal Aid received a cy pres award of over $37,000 stemming from a class action filed by Max Story of the Story Law Group against a local property management company. The suit alleged the Jacksonville-based company charged tenants unlawful fees after they had moved out.

Context: Cy pres awards — residual class-action funds redirected to a charitable purpose approximating the class's interests — occasionally surface in trust and estate practice when a charitable bequest's original purpose fails. Minor here, but a useful reminder of the doctrine for any attorney drafting charitable gifts.

Ken Griffin Assembles Miami Parcels Around New Citadel HQ

Ken Griffin has bought up land around his planned Citadel headquarters in Miami, including all 138 units in a condo building across the street, and reportedly wants to acquire an old cottage across from the site as well.

Context: A tangential Florida data point rather than an estate-planning development: Griffin's 2022 relocation of Citadel from Chicago to Miami remains the marquee example of Florida's no-income-tax, no-estate-tax draw for high-net-worth individuals — the same pitch that lands snowbird clients in Volusia County. Clip angle: 'Why the wealthiest Americans keep moving to Florida — and what it means for your estate plan.'

Multi-State Parasite Outbreak Traced to Taco Bell Lettuce — Thousands Reportedly Sickened

US regulators said a parasite outbreak that has sickened thousands of people across several states was traced to shredded iceberg lettuce served at Taco Bell restaurants, according to Bloomberg's report. The disclosure moved restaurant stocks, with Sweetgreen shares paring a four-day decline after the source was tied to Taco Bell rather than to Sweetgreen.

Context: This is the item to watch. A regulator-confirmed source, a defined product (shredded iceberg lettuce), a defined defendant chain, and a case count reportedly in the thousands are the classic ingredients of a foodborne-illness mass action — cyclospora and similar parasite outbreaks have produced multidistrict settlements before. Signal Strength: 7/10. Plaintiff Profile: Taco Bell customers in the affected states who suffered gastrointestinal parasitic illness within the outbreak window. Next Step: Identify the confirming agency (likely FDA/CDC) and the specific states and product lot/supplier in the traceback, and begin building a case count against both Taco Bell and the upstream lettuce processor — supplier identity determines where the real balance-sheet exposure sits. Confirm the parasite (reportedly cyclospora-type) and the exact number sickened before making representations; the Bloomberg summary does not name them.

GM Coolant-Leak Defect Suit Targets Chevrolet, GMC, and Buick Vehicles

A new class action claims certain Chevrolet, GMC, and Buick vehicles have an engine defect that causes coolant to leak, and that General Motors knew about the defect when it leased or sold the vehicles.

Context: Worth flagging as an early automotive-defect signal: a knowledge-based ('knew about it') pleading against GM across three brands is the kind of case that can grow if it maps to a common engine platform and correlates with a NHTSA complaint cluster or a technical service bulletin. Signal Strength: 4/10 at this stage. Plaintiff Profile: Owners and lessees of the affected Chevrolet, GMC, and Buick models. Next Step: Confirm the specific engine/model years pleaded and cross-reference NHTSA complaint volume and any GM TSBs before assessing whether this is a single-plant defect or a platform-wide exposure.

First Atmosphere Detected on a Rocky Planet in a Star's Habitable Zone

Researchers have found an Earth-like, rocky planet orbiting within the habitable zone of a distant star that possesses an atmosphere. It is the first detection of an atmosphere around a rocky planet in a habitable zone.

Context: Atmosphere detection is the threshold event in the search for life — without one, habitability is moot. This is the kind of milestone that keeps the multi-billion-dollar case for next-generation telescopes (and the private space-instrument supply chain behind them) alive.

Repurposed Spinal-Injury Drug Targets Alzheimer's Through DNA Repair — and Already Cleared Safety Testing

In mouse studies, KCL-286 — a drug originally developed for spinal cord injury — repaired DNA damage, reduced brain inflammation, and hit multiple disease pathways rather than targeting amyloid or tau alone. Because it has already cleared an initial human safety trial, researchers believe it could move relatively quickly into Alzheimer's clinical testing.

Context: The commercial angle is speed: a compound that has passed Phase 1 safety can skip years of the most failure-prone regulatory gauntlet. After a decade of costly amyloid-only failures, a multi-pathway mechanism is exactly the differentiation pharma is hunting for — though mouse-stage efficacy remains a long way from an approved drug.

Sugar-Coated Nanoparticles Smuggle Gene Therapy Past the Blood-Brain Barrier

An experimental glioblastoma treatment uses sugar-coated nanoparticles to ferry genetic instructions across the blood-brain barrier and restore a tumor-suppressing protein directly inside brain cancer cells. In mice, the therapy raised median survival by 50% and shrank tumors without noticeable damage to other organs.

Context: The blood-brain barrier is the single biggest reason CNS drugs fail — most molecules simply can't get in. A reliable delivery vehicle is worth more than any one payload: solve the transport problem and you unlock a platform applicable across brain cancers and neurodegenerative disease.

Finerenone Expands Its Market: Slows Kidney Decline in Non-Diabetic Patients

An international study found that finerenone slows kidney function decline and reduces serious kidney and cardiovascular complications in people with chronic kidney disease who do not have diabetes. The results could open a new treatment option for the majority of CKD patients, who have long had limited choices.

Context: Finerenone (Bayer's Kerendia) was approved for diabetic kidney disease; extending efficacy to the far larger non-diabetic CKD population is a classic label-expansion play that can multiply a drug's addressable market without a new molecule.

Bacteria-Powered 'Living Plastic' Fully Self-Destructs in Six Days

Researchers created a self-destructing 'living plastic' embedded with engineered bacteria that completely break the material down when activated. It degrades in six days and, notably, leaves behind no microplastics.

Context: The microplastic-free claim is the commercially important detail — most 'biodegradable' plastics fragment rather than fully break down, a distinction regulators and packaging buyers are increasingly scrutinizing. Scale-up cost and shelf-life control (you don't want it degrading on the shelf) are the questions that determine whether this leaves the lab.

Earth's Hidden 'Thermostat': How Sea Levels Have Buried Carbon for Millions of Years

Scientists identified a feedback loop that helps explain how Earth has regulated its climate over tens of millions of years. Rising and falling sea levels changed how much phosphate reached the open ocean, altering marine life and the amount of carbon buried beneath the seafloor — a burial process that removed CO₂ from the atmosphere and cooled the planet.

Context: Understanding natural carbon-burial mechanisms sharpens the debate over engineered carbon sequestration and 'blue carbon' credits — knowing the geological baseline is essential to pricing what human intervention can and can't accelerate.

A Sea Worm's 'Bio-Metal' Jaws Point to a New Materials Category

Researchers found that an ancient sea worm's jaws combine proteins and metal ions in a way that produces metal-like strength and unusual mechanical behavior while remaining distinct from traditional metals. They believe these 'bio-metals' could open new directions in materials science.

Context: Biologically-templated materials that match metal performance without metal-scale energy and mining inputs are a live frontier in advanced manufacturing. Early-stage and speculative, but the kind of foundational discovery that underlies patents decades later.

923-Mile AMG GT R Roadster — One of 750, Effectively New

A 2020 Mercedes-AMG GT R roadster, one of 750 produced worldwide for a single model year, with just 923 miles. Finished in Designo Graphite Gray Magno over Black Exclusive Nappa, it carries the AMG Exterior Carbon Fiber Package, Burmester audio, rear-axle steering, and a twin-turbo 4.0-liter V8 with a seven-speed dual-clutch. Original owner until 2026; now offered by the selling dealer with owner's manual, cover, and battery tender.

Context: The GT R Roadster was the top of the pre-facelift AMG GT line and one of the last analog-feeling front-engine V8 Mercedes before the platform's electrification pivot. Sub-1,000-mile examples of a 750-unit single-year car are the kind of thing that gets tucked away and appreciates rather than depreciating like a normal used AMG.

No-Reserve GT350 With the Voodoo V8 — The Last Great Manual Mustang

A 2016 Shelby GT350 in Oxford White with blue stripes, powered by the 5.2-liter flat-plane-crank Voodoo V8 and a six-speed manual with a Torsen limited-slip. Includes the Technology Package, Brembos, and long-tube headers (catalysts removed). 59k miles, clean title, offered in California at no reserve.

Context: The naturally-aspirated, 8,250-rpm Voodoo engine is already recognized as a future collectible — Ford will not build another manual, high-revving NA V8 Mustang. At no reserve with 59k honest miles, this is a driver-grade entry into a car whose clean, low-mile examples are steadily climbing. The removed cats are a smog-state consideration worth pricing in.

2,800-Mile 328i xDrive Wagon — A Time-Capsule Manual-Era Longroof

A 2016 BMW 328i xDrive Sports Wagon, single-owner in California until 2026, with just 2,800 miles. Jet Black over Black Dakota, turbo 2.0-liter four with all-wheel drive and an eight-speed auto, loaded with Driver Assistance Plus, Cold Weather, and Premium Packages, panoramic roof, and Harman Kardon. Offered at no reserve.

Context: BMW barely sold the 3 Series wagon in the U.S., which is exactly why enthusiasts hunt them — a practical, AWD, understated longroof from the last generation before BMW's styling and reliability took a controversial turn. A genuine 2,800-mile example is essentially unrepeatable; the delivery-mileage rarity is the story here.

2005 LX470 at No Reserve — Overlanding's Bulletproof Bargain

A 2005 Lexus LX470 in Blue Vapor Metallic over Ivory, with the 4.7-liter V8, dual-range transfer case, Adaptive Variable Suspension, and a Gamiviti roof rack. Three rows, Mark Levinson audio, 188k miles, sold on BaT twice previously, now offered at no reserve with a clean Carfax and clean New York title.

Context: The LX470 is a Land Cruiser 100-series in a tuxedo — the 2UZ-FE V8 routinely runs past 300k miles, and clean examples have become a serious overlanding platform as 80- and 100-series values climb. At no reserve with an already-fitted rack, this is one of the last affordable ways into a genuinely indestructible full-size 4x4.

Roush 347-Powered Factory Five Cobra — Cobra Thrills at a Fraction of Cobra Money

A Factory Five Racing Mk4 Roadster with a Roush 347ci stroker V8, electronic fuel injection, and a Tremec TKO 600 five-speed. Black with over-the-top stripes, adjustable coilovers, Wilwood discs, Halibrand-style 18s, and side-exit exhaust. Acquired by the current owner in 2024, offered by a BaT Local Partner dealer.

Context: A real 289/427 Cobra runs into the seven figures; a well-built Factory Five delivers the same 2,400-lb, side-pipe visceral experience for the price of a used pickup. A Roush-crate 347 and a Tremec TKO 600 is the desirable spec — this is the sensible man's way to own the shape.